Q2 2019 EPS Estimates for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Increased by Analyst

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Equities researchers at Svb Leerink boosted their Q2 2019 earnings per share estimates for Alexion Pharmaceuticals in a research note issued on Tuesday, July 16th. Svb Leerink analyst G. Porges now forecasts that the biopharmaceutical company will post earnings of $2.32 per share for the quarter, up from their prior forecast of $2.26. Svb Leerink also issued estimates for Alexion Pharmaceuticals’ Q3 2019 earnings at $2.28 EPS, Q4 2019 earnings at $2.31 EPS and FY2019 earnings at $9.15 EPS.

Other analysts have also issued reports about the company. TheStreet lowered Trinity Industries from a “b” rating to a “c” rating in a report on Thursday, April 25th. BidaskClub downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 9th. Royal Bank of Canada lowered their price objective on Gildan Activewear from $34.00 to $33.00 and set a “sector perform” rating for the company in a research report on Wednesday, March 27th. Citigroup downgraded Barrick Gold to a “neutral” rating in a report on Thursday, May 23rd. Finally, Wedbush set a $190.00 target price on Home Depot and gave the stock a “hold” rating in a report on Wednesday, May 22nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $161.06.

ALXN opened at $120.80 on Thursday. The firm has a market cap of $27.09 billion, a price-to-earnings ratio of 17.04, a P/E/G ratio of 0.92 and a beta of 1.64. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86. The company has a current ratio of 3.87, a quick ratio of 3.36 and a debt-to-equity ratio of 0.25. The stock’s fifty day moving average is $123.56.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.40. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.68 EPS.

In related news, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the transaction, the executive vice president now owns 29,627 shares in the company, valued at $3,933,873.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker sold 123,489 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $126.53, for a total value of $15,625,063.17. The disclosure for this sale can be found here. Insiders have sold 428,567 shares of company stock worth $53,420,869 over the last quarter. 4.08% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC raised its stake in Alexion Pharmaceuticals by 25.1% in the fourth quarter. FMR LLC now owns 26,398,265 shares of the biopharmaceutical company’s stock worth $2,570,135,000 after buying an additional 5,301,272 shares in the last quarter. Norges Bank purchased a new stake in shares of Alexion Pharmaceuticals during the 4th quarter worth about $388,934,000. Artisan Partners Limited Partnership boosted its stake in shares of Alexion Pharmaceuticals by 220.9% during the 1st quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after acquiring an additional 2,924,550 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Alexion Pharmaceuticals by 17.3% during the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after acquiring an additional 1,512,545 shares in the last quarter. Finally, FIL Ltd boosted its stake in shares of Alexion Pharmaceuticals by 629.3% during the 1st quarter. FIL Ltd now owns 1,208,567 shares of the biopharmaceutical company’s stock worth $163,373,000 after acquiring an additional 1,042,846 shares in the last quarter. Hedge funds and other institutional investors own 94.74% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: Google Finance Portfolio

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.